-
公开(公告)号：US10716832B2
公开(公告)日：2020-07-21
申请号：US15488764
申请日：2017-04-17
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
-
公开(公告)号：US20230134568A1
公开(公告)日：2023-05-04
申请号：US17818276
申请日：2022-08-08
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
IPC: A61K38/20 , C07K16/24 , A61K38/17 , C07K14/545 , A61P19/02 , A61K39/395 , G01N33/68
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
-
公开(公告)号：US11406688B2
公开(公告)日：2022-08-09
申请号：US16947126
申请日：2020-07-20
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
IPC: C07H21/04 , A61K38/20 , C07K16/24 , A61K38/17 , C07K14/545 , A61P19/02 , A61K39/395 , G01N33/68
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
-
Patent Agency Ranking
公开(公告)号：US09649361B2
公开(公告)日：2017-05-16
申请号：US14942841
申请日：2015-11-16
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
CPC classification number: A61K38/2006 , A61K38/1709 , C07K14/545 , C07K16/245 , G01N33/6869 , Y10S514/825
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
-
公开(公告)号：US20200345813A1
公开(公告)日：2020-11-05
申请号：US16947126
申请日：2020-07-20
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
IPC: A61K38/20 , C07K16/24 , A61K38/17 , C07K14/545 , G01N33/68
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
-
公开(公告)号：US20170281730A1
公开(公告)日：2017-10-05
申请号：US15488764
申请日：2017-04-17
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
IPC: A61K38/20 , A61K38/17 , G01N33/68 , C07K16/24 , C07K14/545
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
-
公开(公告)号：US20160067310A1
公开(公告)日：2016-03-10
申请号：US14942841
申请日：2015-11-16
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , Maria Virginia Pascual
IPC: A61K38/20
CPC classification number: A61K38/2006 , A61K38/1709 , C07K14/545 , C07K16/245 , G01N33/6869 , Y10S514/825
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
Abstract translation: 本发明包括用于治疗患有自身炎症的患者的关节炎关节的组合物和方法，例如全身性发作的幼年特发性关节炎，通过在炎症部位施用治疗有效量的至少一种降低或阻断白介素 - 1＆bgr
-
公开(公告)号：US20150133469A1
公开(公告)日：2015-05-14
申请号：US14384891
申请日：2013-03-13
Applicant: BAYLOR RESEARCH INSTITUTE , MEDICAL RESEARCH COUNCIL , IMPERIAL COLLEGE HEATHCARE NHS TRUST
Inventor： Anne O'Garra , Chloe Bloom , Matthew Paul Reddoch Berry , Robert Wilkinson , Jacques F. Banchereau , Damien Chaussabel , Maria Virginia Pascual
IPC: C12Q1/68 , A61K31/133 , A61K31/455 , A61K31/496 , A61K31/4965
CPC classification number: C12Q1/6883 , A61K31/133 , A61K31/455 , A61K31/496 , A61K31/4965 , C12Q1/68 , C12Q2600/118 , C12Q2600/158 , G01N33/48 , G01N33/68 , G01N33/6893 , G01N2333/35 , G01N2800/26 , G01N2800/52
Abstract: The present invention includes methods for early detection of a treatment response in a patient suspected of being infected with Mycobacterium tuberculosis. Changes in the blood transcriptome are detectable within two weeks of the initiation of antituberculosis therapy.
Abstract translation: 本发明包括在怀疑感染结核分枝杆菌的患者中早期检测治疗反应的方法。 在抗结核治疗开始后两周内，血液转录组的变化是可检测的。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.019 seconds)
